Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy By: Benzinga via Benzinga February 22, 2018 at 10:33 AM EST The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s prospects. But the generic drug developer ... Read More >> Related Stocks: Momenta Pharma